ME Therapeutics Advances In Vivo CAR-T and mRNA Programs Targeting Hematologic and Solid Tumors

Apr 29, 2026-

ME Therapeutics Holdings Inc. has announced continued progress across its in vivo CAR-T and therapeutic mRNA platforms, highlighting a dual-track strategy aimed at expanding the reach of immuno-oncology beyond traditional approaches.

At the center of its pipeline is a dual CD19/CD22-targeted in vivo CAR program, designed to address hematologic malignancies such as leukemia and lymphoma, as well as select autoimmune diseases. The construct combines a clinically validated CD19 CAR with a newly licensed CD22 nanobody, aiming to improve targeting precision and reduce antigen escape—a known limitation in single-target CAR-T therapies.

Unlike conventional ex vivo CAR-T, ME Therapeutics is developing an in vivo approach, where CAR-encoding mRNA is delivered directly into the body. This eliminates the need for complex cell extraction, engineering, and reinfusion processes.

To enable this, the company is optimizing Lipid Nanoparticle (LNP) formulations designed to efficiently deliver mRNA into T cells and myeloid cells in vivo. Once optimized, the lead CAR candidates will be evaluated in humanized mouse cancer models, a key step toward clinical translation.

In parallel, ME Therapeutics is advancing a therapeutic mRNA program targeting the STING pathway, a well-established driver of anti-tumor immune responses. The company reported dose-dependent efficacy in a colorectal cancer mouse model, with further optimization efforts focused on enhancing STING expression specifically within the tumor microenvironment.

The STING pathway has long been considered a promising but challenging target in oncology due to delivery and toxicity limitations. By leveraging mRNA-based expression, ME Therapeutics aims to achieve more controlled and localized activation, potentially improving both safety and efficacy.

Two optimized variants of the STING mRNA candidate have now been selected for further development, signaling continued momentum in the program.

Together, these efforts reflect a broader shift in the field toward in vivo cell engineering and mRNA-based therapeutics, where delivery technologies like LNPs are enabling more scalable, off-the-shelf immunotherapies.

While still in the preclinical stage, ME Therapeutics’ approach underscores the growing convergence of mRNA technology and cell therapy, with the potential to simplify manufacturing, reduce costs, and expand patient access across both hematologic and solid tumors.